SemBioSys Genetics

Description

Our plant technology offers dramatic scalability and economic advantages compared to existing production methods. We believe that these same advantages which drive our pharmaceutical opportunities also open new non-pharmaceutical markets in the areas of agricultural biotechnology, nutritional supplements and personal care ingredients. Our technology uses the natural manufacturing advantages of safflower to produce, extract and purify high-value, high-volume products from plants as an alternative to the traditional fermentation-based processes used today. We believe that this technology will produce a cost-effective source of pharmaceutical proteins which could provide access to life-saving therapies to underserved markets in Asia and the developing world. Thanks to our strong leadership we're already seeing positive results. Our plant-derived insulin is on the verge of entering clinical trials and as such, is one step closer to being engaged in a partnership. Our cardiovascular innovation, Apo AI is currently in preclinical testing, the results from which could attract significant interest from pharmaceutical companies. While these two products represent long-term success, in the short-term, our subsidiary Botaneco and its in-market and growing line-up of personal care products is delivering value.

Products & services

Similar companies nearby